Switch theme
Sign up to access all valuation multiples
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
1987
6.6K+
LTM Revenue $2.8B
LTM EBITDA $563M
$4.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
QuidelOrtho has a last 12-month revenue (LTM) of $2.8B and a last 12-month EBITDA of $563M.
In the most recent fiscal year, QuidelOrtho achieved revenue of $2.8B and an EBITDA of -$1.5B.
QuidelOrtho expects next 12-month revenue of XXX and NTM EBITDA of XXX
See QuidelOrtho valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | $563M | XXX | -$1.5B | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | -54% | XXX | XXX | XXX |
| EBIT | $349M | XXX | $45.8M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $141M | XXX | -$2.1B | XXX | XXX | XXX |
| Net Margin | 5% | XXX | -74% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, QuidelOrtho's stock price is $31.
QuidelOrtho has current market cap of $2.1B, and EV of $4.6B.
See QuidelOrtho trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.6B | $2.1B | XXX | XXX | XXX | XXX | $2.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, QuidelOrtho has market cap of $2.1B and EV of $4.6B.
QuidelOrtho's trades at 1.7x EV/Revenue multiple, and -3.1x EV/EBITDA.
Equity research analysts estimate QuidelOrtho's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
QuidelOrtho has a P/E ratio of 14.7x.
See valuation multiples for QuidelOrtho and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $4.6B | XXX | $4.6B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 8.2x | XXX | -3.1x | XXX | XXX | XXX |
| EV/EBIT | 13.3x | XXX | 101.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.7x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | 25.8x | XXX | -41.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQuidelOrtho's last 12 month revenue growth is 0%
QuidelOrtho's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
QuidelOrtho's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
QuidelOrtho's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for QuidelOrtho and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | -54% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | -53% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
QuidelOrtho acquired XXX companies to date.
Last acquisition by QuidelOrtho was XXXXXXXX, XXXXX XXXXX XXXXXX . QuidelOrtho acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was QuidelOrtho founded? | QuidelOrtho was founded in 1987. |
| Where is QuidelOrtho headquartered? | QuidelOrtho is headquartered in United States of America. |
| How many employees does QuidelOrtho have? | As of today, QuidelOrtho has 6.6K+ employees. |
| Who is the CEO of QuidelOrtho? | QuidelOrtho's CEO is Mr. Brian J. Blaser. |
| Is QuidelOrtho publicy listed? | Yes, QuidelOrtho is a public company listed on NAS. |
| What is the stock symbol of QuidelOrtho? | QuidelOrtho trades under QDEL ticker. |
| When did QuidelOrtho go public? | QuidelOrtho went public in 1992. |
| Who are competitors of QuidelOrtho? | Similar companies to QuidelOrtho include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of QuidelOrtho? | QuidelOrtho's current market cap is $2.1B |
| What is the current revenue of QuidelOrtho? | QuidelOrtho's last 12 months revenue is $2.8B. |
| What is the current revenue growth of QuidelOrtho? | QuidelOrtho revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of QuidelOrtho? | Current revenue multiple of QuidelOrtho is 1.7x. |
| Is QuidelOrtho profitable? | Yes, QuidelOrtho is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of QuidelOrtho? | QuidelOrtho's last 12 months EBITDA is $563M. |
| What is QuidelOrtho's EBITDA margin? | QuidelOrtho's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of QuidelOrtho? | Current EBITDA multiple of QuidelOrtho is 8.2x. |
| What is the current FCF of QuidelOrtho? | QuidelOrtho's last 12 months FCF is $180M. |
| What is QuidelOrtho's FCF margin? | QuidelOrtho's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of QuidelOrtho? | Current FCF multiple of QuidelOrtho is 25.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
